Audentes Therapeutics, Inc
BOLD
BOLD was delisted on the 14th of January, 2020.
149 hedge funds and large institutions have $1.25B invested in Audentes Therapeutics, Inc in 2019 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 64 increasing their positions, 34 reducing their positions, and 16 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 34
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
1% more funds holding
Funds holding: 147 → 149 (+2)
26% less capital invested
Capital invested by funds: $1.69B → $1.25B (-$438M)
49% less call options, than puts
Call options by funds: $1.1M | Put options by funds: $2.15M
63% less funds holding in top 10
Funds holding in top 10: 8 → 3 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$21.7M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$19.2M |
| 3 |
BlackRock
New York
|
+$12.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.8M |
| 5 |
Millennium Management
New York
|
+$8.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$31.2M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$24.1M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$11M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$10.5M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.52M |
BOLD Hedge Fund Activity: Q3 2019 in Review
149 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q3 2019, worth a combined $1.25B — down 26% from $1.69B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new BOLD positions and 16 closed out — a net gain of 4 holders — while 64 added to existing stakes and 34 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $21.7M. The largest seller was PFM Health Sciences, cutting an estimated $31.2M.
- 149 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q3 2019, up from 147 in Q2 2019.
- Funds reported $1.25B of Audentes Therapeutics, Inc stock for Q3 2019, down 26% quarter-over-quarter.
- 20 funds opened new Audentes Therapeutics, Inc positions in Q3 2019 and 16 closed out, a net change of +4 holders.
- The largest Audentes Therapeutics, Inc buyer in Q3 2019 was Armistice Capital, an estimated $21.7M added.
- The largest Audentes Therapeutics, Inc seller in Q3 2019 was PFM Health Sciences, an estimated $31.2M sold.
Based on aggregated 13F filings for Q3 2019.